Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other financing activities: 2016-2024

Historic Other financing activities for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to -$377,000.

  • Aclaris Therapeutics' Other financing activities rose 164.79% to $300,000 in Q2 2021 from the same period last year, while for Jun 2021 it was -$289,000, marking a year-over-year increase of 25.90%. This contributed to the annual value of -$377,000 for FY2024, which is 4612.50% down from last year.
  • Aclaris Therapeutics' Other financing activities amounted to -$377,000 in FY2024, which was down 4,612.50% from -$8,000 recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Other financing activities ranged from a high of $211,000 in FY2020 and a low of -$1.6 million during FY2021.
  • In the last 2 years, Aclaris Therapeutics' Other financing activities had a median value of -$192,500 in 2023 and averaged -$192,500.
  • Its Other financing activities has fluctuated over the past 5 years, first skyrocketed by 655.26% in 2020, then slumped by 4,612.50% in 2024.
  • Over the past 4 years, Aclaris Therapeutics' Other financing activities (Yearly) stood at $211,000 in 2020, then crashed by 845.97% to -$1.6 million in 2021, then reached -$8,000 in 2023, then plummeted by 4,612.50% to -$377,000 in 2024.